Featured Research

from universities, journals, and other organizations

Iron compounds synthesized to combat tuberculosis

Date:
November 29, 2010
Source:
Plataforma SINC
Summary:
Researchers have synthesized two iron compounds that inhibit the in vitro growth of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. Due their low level of toxicity in mammal cells, the compounds could be used in the future as therapeutic agents and hospital disinfectants.

The new compounds have show promise against the Mycobacterium bacterium tuberculosis.
Credit: CDC/George P. Kubica

A team of researchers from Spain and Latin America have synthesized two iron compounds that inhibit the in vitro growth of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. Due their low level of toxicity in mammal cells, the compounds could be used in the future as therapeutic agents and hospital disinfectants.

A group of researchers from the Universidad de Navarra (Spain), the Universidad de la República (Uruguay), the Universidad de São Paulo (Brazil) and the Universidad Nacional de La Plata (Argentina) have synthesized two iron complexes "that showed in vitro growth inhibitory activity on Mycobacterium tuberculosis," Dinorah Gambino and María Torre, authors of the study and researchers at the Universidad de la República explained.

The study, published this month by the Journal of Inorganic Biochemistry uses iron atoms to join organic molecules (derived from quinoxaline), forming compounds that act as bactericides (killing bacteria) or bacteriostatic agents (preventing bacteria from reproducing). The organic molecules were synthesized at the Universidad de Navarra.

"One of the greatest problems in relation to the pharmacotherapy for treating tuberculosis is the appearance of bacteria resistant to current medicines, which is why it is important to develop new active ingredients," the researchers indicate.

In order to treat tuberculosis, initially "first-line" antibiotics are used (such as isoniacide or estreptomicine ), but when side effects appear, or in cases of stronger resistance, "second-line" antibiotics are resorted to (such as cicloserine or ciprofloxacine ). The new compounds inhibit M. tuberculosis better than the "second-line" medicines.

Low Toxicity

Another advantage of the iron compounds is that they show low toxicity in mammal cells, as demonstrated by the experiments performed with mice cells. "That is why these compounds are useful as hospital disinfectants or therapeutic agents," the Uruguayan researchers highlight, albeit recalling that, at present, they in vitro trials "and the line of research remains open to learn more about how they act."

Antonio Monge, co-author of the study and a researcher at the Universidad de Navarra, underlines the importance of cooperating with research centres in Latin America, where there are many cases of tuberculosis and other diseases such as malaria or chagas disease. "This type of cooperation always benefits the person who is suffering."

Tuberculosis kills more than one million people a year worldwide (1.3 million in 2008). Various Mycobacterium species -- particularly M. tuberculosis- are the cause.

At present, tuberculosis is considered a re-emerging disease due to the increase in the number of people with HIV and other viruses that attack the immune system, as well as to the increasing consumption of immunosuppressive and recreational drugs. The World Health Organization (WHO) estimates that 30 million people will be infected by tuberculosis over the next 20 years.


Story Source:

The above story is based on materials provided by Plataforma SINC. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Belén Tarallo, Carolina Urquiola, Antonio Monge, Beatriz Parajón Costa, Ronny R. Ribeiro, Antonio J. Costa-Filho, Roberto C. Mercader, Fernando R. Pavan, Clarice Q.F. Leite, María H. Torre. Design of novel iron compounds as potential therapeutic agents against tuberculosis☆. Journal of Inorganic Biochemistry, 2010; 104 (11): 1164 DOI: 10.1016/j.jinorgbio.2010.07.005

Cite This Page:

Plataforma SINC. "Iron compounds synthesized to combat tuberculosis." ScienceDaily. ScienceDaily, 29 November 2010. <www.sciencedaily.com/releases/2010/11/101126094446.htm>.
Plataforma SINC. (2010, November 29). Iron compounds synthesized to combat tuberculosis. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/11/101126094446.htm
Plataforma SINC. "Iron compounds synthesized to combat tuberculosis." ScienceDaily. www.sciencedaily.com/releases/2010/11/101126094446.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins